Therefore, for cancers with an overexpression of Mdm2/MdmX, developing effective inhibitors that target Mdm2/MdmX to release p53 and restore its normal tumor-suppressive function could provide new approaches to overcoming the challenges of cancer prevention and treatment. Here, TP53 is linked to neoplasm.